Actively Recruiting

Age: 18Years +
All Genders
ID04516720

Creation of a Clinical Database on Primary Nervous System Tumors

Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12

1700

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Primary central nervous system tumors (PCNST) include various types of tumors affecting the brain, spinal cord, meninges, and nerves. These tumors can be benign, malignant, or borderline and have over 140 subtypes with different causes, prognoses, and treatments. Due to their rarity and diversity, there is limited knowledge about many PCNST subtypes, making the creation of a comprehensive clinical database important for research on tumor characteristics, treatment impact, and survival outcomes. This study involves collecting detailed clinical, radiological, and biological data from patients with PCNST treated at the Montpellier Cancer Institute. It includes both retrospective data from patients treated since 2004 and prospective data from ongoing patients. The database will gather information on tumor diagnosis, treatments received, and follow-up until death or progression, aiming to support clinical and epidemiological studies and facilitate patient identification for future research. Participants in this observational study provide information through their medical records and questionnaires. Researchers will track outcomes such as tumor progression and survival for up to 100 months after inclusion. The study collects data systematically to analyze predictive factors and prognosis across different tumor subtypes. Participation involves data sharing, and patients' clinical course is monitored over time without altering their standard care.

CONDITIONS

Brief Title

Creation of a Clinical Database on Primary Nervous System Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patient aged 60; 18, no upper age limit
  • Diagnosis of Primary central nervous system tumors
  • Patient treated at the Montpellier Cancer Institute, regardless of treatment type
  • For retrospective study: treated at the Montpellier Cancer Institute between January 1, 2004 and study start
  • Patient informed and consents to participate in retrospective or prospective study
Not Eligible

You will not qualify if you...

  • Secondary lesions of the central nervous system
  • Patient not affiliated with a social protection scheme
  • Subject under tutelage, curatorship, or legal protection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - From date of inclusion until the date of first documented progression or death, assessed up to 100 months

Participants have diagnostic data collected including symptoms, radiological and histological diagnosis, tumor characteristics, and molecular data.

Data collected from medical records; visit frequency varies

Long-term Monitoring

Duration - From date of inclusion until the date of first documented progression or death, assessed up to 100 months

Participants are followed over time to observe treatment sequences, oncological treatments, toxicities, and survival outcomes.

Data collection occurs throughout treatment and follow-up; visit frequency varies

Trial Site Locations

Total: 1 location

1

Icm Val D'Aurelle

Montpellier, Herault, France, 34298

Actively Recruiting

Loading map...

Research Team

A

Aurore MOUSSION, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Quinn T Ostrom, Haley Gittleman, Jordonna Fulop...

https://pubmed.ncbi.nlm.nih.gov/26511214

Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.

Laurent Capelle, Denys Fontaine, Emmanuel Mandonnet...

https://pubmed.ncbi.nlm.nih.gov/23495881